Market closed
Amphastar Pharmaceuticals/$AMPH
Amphastar Pharmaceuticals shares are trading lower despite reporting Q1 earnings that exceeded estimates.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Ticker
$AMPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
2,028
ISIN
US03209R1032
Website
AMPH Metrics
BasicAdvanced
$1.2B
8.91
$2.77
0.78
-
Price and volume
Market cap
$1.2B
Beta
0.78
52-week high
$52.05
52-week low
$22.64
Average daily volume
635K
Financial strength
Current ratio
2.954
Quick ratio
1.92
Long term debt to equity
85.795
Total debt to equity
86.856
Interest coverage (TTM)
5.90%
Management effectiveness
Return on assets (TTM)
7.60%
Return on equity (TTM)
19.90%
Valuation
Price to earnings (TTM)
8.914
Price to revenue (TTM)
1.629
Price to book
1.56
Price to tangible book (TTM)
7.05
Growth
Revenue change (TTM)
8.05%
Earnings per share change (TTM)
-4.83%
3-year revenue growth (CAGR)
17.09%
3-year earnings per share growth (CAGR)
19.48%
What the Analysts think about AMPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
AMPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AMPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AMPH News
AllArticlesVideos
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Accesswire·11 hours ago
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amphastar Pharmaceuticals stock?
Amphastar Pharmaceuticals (AMPH) has a market cap of $1.2B as of May 09, 2025.
What is the P/E ratio for Amphastar Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amphastar Pharmaceuticals (AMPH) stock is 8.91 as of May 09, 2025.
Does Amphastar Pharmaceuticals stock pay dividends?
No, Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Amphastar Pharmaceuticals dividend payment date?
Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals (AMPH) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.